Clusters that facilitate Covid-19 transmission in Colombia

Conglomerados que favorecen la transmisión del COVID-19 en Colombia

Introduction: in late 2019, a novel beta coronavirus, later known as SARS-CoV-2, infection was reported in people who had been exposed to a seafood market in Wuhan, China, where live animals were sold. Since then there has been a rapid spread of the virus, causing a global COVID-19 pandemic. Objective: to conduct a statistical analysis of clusters of COVID-19 transmission in Colombia. Methodology: this research was focused on COVID-19 clusters, their size, confirmed cases, testing, deaths and positivity rate, from information obtained by the National Institute of Health. Results: the companies setting accounts for the greatest number of clusters of COVID-19 transmission, 481, followed by 320 in healthcare institutions. It was observed that the armed forces cluster had the highest number of confirmed cases reaching a total of 12.555, followed by 5.887 in companies. COVID-19 testing was conducted mostly in the armed forces in 29.781 individuals, followed by the companies in 27.118. Likewise, the highest number of fatalities occurred in the welfare center cluster reaching a total of 185, followed by 64 in the armed forces; the armed forces cluster had the highest COVID-19 positivity rate of 42.16 %, followed by 39.29 % in the prison system. Conclusion: clusters must address some conditions, such as proximity, people, length of stay, and instability of COVID-19 protective measures, in addition to the density of people in confined spaces.

1. Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med. 2020;383(18):1757-66. doi: 10.1056/NEJMcp2009249
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. doi: 10.1056/NEJMoa2001017
3. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80 e8. doi:10.1016/j.cell.2020.02.052
4. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020. MMWR Morbidity and mortality weekly report. 2020;69(14):411-5. doi: 10.15585 / mmwr.mm6914e1
5. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564-7. D doi: 10.1056/NEJMc2004973.
6. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. The Journal of hospital infection. 2020;104(3):246-51. Epub 2020/02/10.
7. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) [Internet]. Washington, D.C. : Department of Health and Human Services; 2020 [cited 2020 octubre]; Available from: https://www.cdc.gov/other/language-assistance.html#Spanish.
8. Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020. MMWR Morbidity and mortality weekly report. 2020;69(13):377-81. doi: 10.15585/mmwr.mm6913e1.
9. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nature medicine. 2020;26(5):672-5. doi: 10.1038/s41591-020-0869-5.
10. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465-9. doi: 10.1038/s41586-020-2196-x.
11. Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. The Lancet Infectious diseases. 2020;20(6):656-7. Epub 2020/03/23.
12. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Annals of internal medicine. 2020;172(9):577-82.
13. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9. Epub 2020/02/08.
14. Díaz-Pinzón JE. Simulador Applet Descartes: Como didáctica de enseñanza de la función cuadrática. INNOVA Research Journal 2017;2(8):69-78.
15. Instituto Nacional de Salud. Coronavirus (COVID-2019) en Colombia[Internet] Colombia: Instituto Nacional de Salud; 2020 [cited 2020 noviembre 2]; Available from: https://www.minsalud.gov.co/salud/publica/PET/Paginas/Covid-19_copia.aspx.
16. Díaz-Pinzón JE. Precisión del pronóstico de la propagación del COVID-19 en Colombia. Repert Med Cir. 2020;29(Núm. Supl.1):27- 33. doi: 10.31260/RepertMedCir.01217372.1045.